Federal Register / Vol. 80, No. 28 / Wednesday, February 11, 2015 / Notices 7633 

health and welfare, (2) competitive 

conditions in the U.S. economy, (3) U.S. 

production of articles that are like or 

directly competitive with those that are 

subject to investigation, and (4) U.S. 

consumers. The Commission is 

therefore interested in receiving written 

submissions that address the 

aforementioned public interest factors 

in the context of this investigation. 

If the Commission orders some form 

of remedy, the U.S. Trade 

Representative, as delegated by the 

President, has 60 days to approve or 

disapprove the Commission’s action. 

See Presidential Memorandum of July 

21, 2005, 70 FR 43251 (July 26, 2005). 

During this period, the subject articles 

would be entitled to enter the United 

States under bond, in an amount 

determined by the Commission and 

prescribed by the Secretary of the 

Treasury. The Commission is therefore 

interested in receiving submissions 

concerning the amount of the bond that 

should be imposed if a remedy is 

ordered. 

Written Submissions: The parties to 

the investigation are requested to file 

written submissions on all of the issues 

identified in this notice. Parties to the 

investigation, interested government 

agencies, and any other interested 

parties are encouraged to file written 

submissions on the issues of remedy, 

the public interest, and bonding. Such 

submissions should address the 

recommended determination by the ALJ 

on remedy and bonding. Complainant 

Springfree is also requested to submit 

proposed remedial orders for the 

Commission’s consideration. Springfree 

is also requested to state the date that 

the asserted patent expires and the 

HTSUS numbers under which the 

accused products are imported, and 

provide identification information for 

all known importers of the subject 

articles. Initial written submissions and 

proposed remedial orders must be filed 

no later than close of business on 

Thursday, February 19, 2015. Initial 

written submissions by the parties shall 

be no more than 40 pages, excluding 

any exhibits. Reply submissions must be 

filed no later than the close of business 

on Monday, March 2, 2015. Reply 

submissions by the parties shall be no 

more than 20 pages, excluding any 

exhibits. No further submissions on 

these issues will be permitted unless 

otherwise ordered by the Commission. 

Persons filing written submissions must 

file the original document electronically 

on or before the deadlines stated above 

and submit 8 true paper copies to the 

Office of the Secretary by noon the next 

day pursuant to section 210.4(f) of the 

Commission’s Rules of Practice and 

Procedure (19 CFR 210.4(f)). 

Submissions should refer to the 

investigation number (‘‘Inv. No. 337– 

TA–908’’) in a prominent place on the 

cover page and/or the first page. (See 

Handbook for Electronic Filing 

Procedures, http://www.usitc.gov/

secretary/fed_reg_notices/rules/

handbook_on_electronic_filing.pdf). 

Persons with questions regarding filing 

should contact the Secretary (202–205– 

2000). 

Any person desiring to submit a 

document to the Commission in 

confidence must request confidential 

treatment. All such requests should be 

directed to the Secretary to the 

Commission and must include a full 

statement of the reasons why the 

Commission should grant such 

treatment. See 19 CFR 201.6. Documents 

for which confidential treatment by the 

Commission is properly sought will be 

treated accordingly. A redacted nonconfidential version of the document 

must also be filed simultaneously with 

the any confidential filing. All 

nonconfidential written submissions 

will be available for public inspection at 

the Office of the Secretary and on EDIS. 

The authority for the Commission’s 

determination is contained in section 

337 of the Tariff Act of 1930, as 

amended (19 U.S.C. 1337), and in Part 

210 of the Commission’s Rules of 

Practice and Procedure (19 CFR part 

210). 

By order of the Commission. 

Issued: February 5, 2015. 

Lisa R. Barton, 

Secretary to the Commission. 

[FR Doc. 2015–02782 Filed 2–10–15; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: MYODERM 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration in 

accordance with 21 CFR 1301.34(a) on 

or before March 13, 2015. Such persons 

may also file a written request for a 

hearing on the application pursuant to 

21 CFR 1301.43 on or before March 13, 

2015. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/ODW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. Request for hearings should be 

sent to: Drug Enforcement 

Administration, Attention: Hearing 

Clerk/LJ, 8701 Morrissette Drive, 

Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Deputy Assistant 

Administrator of the DEA Office of 

Diversion Control (‘‘Deputy Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part appendix to subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on October 

6, 2014, Myoderm, 48 East Main Street, 

Norristown, Pennsylvania 19401, 

applied to be registered as an importer 

of the following basic classes of 

controlled substances: 

Controlled substance Schedule 

Amphetamine (1100) .................... II 

Lisdexamfetamine (1205) ............. II 

Methylphenidate (1724) ................ II 

Pentobarbital (2270) ..................... II 

Nabilone (7379) ............................ II 

Codeine (9050) ............................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Hydrocodone (9193) ..................... II 

Levomethorphan (9210) ............... II 

Meperidine (9230) ........................ II 

Methadone (9250) ........................ II 

Methadone intermediate (9254) ... II 

Morphine (9300) ........................... II 

Oxymorphone (9652) ................... II 

Fentanyl (9801) ............................ II 

The company plans to import the 

listed controlled substances in finished 

dosage form for clinical trials, and 

research. 

The import of the above listed basic 

classes of controlled substances will be 

granted only for analytical testing and 

clinical trials. This authorization does 

not extend to the import of a finished 

FDA approved or non-approved dosage 

form for commercial distribution in the 

United States. 


tkelley on DSK3SPTVN1PROD with NOTICES
7634 Federal Register / Vol. 80, No. 28 / Wednesday, February 11, 2015 / Notices 

Dated: February 5, 2015. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator. 

[FR Doc. 2015–02823 Filed 2–10–15; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: GE Healthcare 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration in 

accordance with 21 CFR 1301.34(a) on 

or before March 13, 2015. Such persons 

may also file a written request for a 

hearing on the application pursuant to 

21 CFR 1301.43 on or before March 13, 

2015. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/ODW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. Request for hearings should be 

sent to: Drug Enforcement 

Administration, Attention: Hearing 

Clerk/LJ, 8701 Morrissette Drive, 

Springfield, Virginia 22152. Comments 

and request for hearings on applications 

to import narcotic raw material are not 

appropriate. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispenser, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Deputy Assistant 

Administrator of the DEA Office of 

Diversion Control (‘‘Deputy Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on 

September 12, 2014, GE Healthcare, 

3350 North Ridge Avenue, Arlington 

Heights, Illinois 60004–1412 applied to 

be registered as an importer of cocaine 

(9041), a basic class of controlled 

substance listed in schedule II. 

The company plans to import small 

quantities of ioflupane, in the form of 

three separate analogues of cocaine, to 

validate production and quality control 

systems, for a reference standard, and 

for producing material for a future 

investigational new drug (IND) 

submission. 

Dated: February 5, 2015. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator. 

[FR Doc. 2015–02826 Filed 2–10–15; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: Mallinckrodt LLC 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration in 

accordance with 21 CFR 1301.34(a) on 

or before March 13, 2015. Such persons 

may also file a written request for a 

hearing on the application pursuant to 

21 CFR 1301.43 on or before March 13, 

2015. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/ODW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. Request for hearings should be 

sent to: Drug Enforcement 

Administration, Attention: Hearing 

Clerk/LJ, 8701 Morrissette Drive, 

Springfield, Virginia 22152. Comments 

and requests for hearings on 

applications to import narcotic raw 

material are not appropriate. 72 FR 3417 

(January 25, 2007). 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Deputy Assistant 

Administrator of the DEA Office of 

Diversion Control (‘‘Deputy Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on January 

16, 2014, Mallinckrodt LLC, 3600 North 

Second Street, St. Louis, Missouri 

63147, applied to be registered as an 

importer of the following basic classes 

of controlled substances: 

Controlled substance Schedule 

Phenylacetone (8501) .................. II 

Coca Leaves (9040) ..................... II 

Opium, raw (9600) ....................... II 

Poppy Straw Concentrate (9670) II 

The company plans to import the 

listed controlled substances for the 

manufacture of controlled substances in 

bulk for distribution to its customers. 

In reference to Phenylacetone (8501), 

the company plans to import the 

controlled substance for the bulk 

manufacture of amphetamine products 

for sale to its customers. 

Dated: February 5, 2015. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator. 

[FR Doc. 2015–02824 Filed 2–10–15; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Bulk Manufacturer of Controlled 

Substances Application: Siegfried 

USA, LLC 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration in 

accordance with 21 CFR 1301.33(a) on 

or before April 13, 2015. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/ODW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. Request for hearings should be 

sent to: Drug Enforcement 

Administration, Attention: Hearing 

Clerk/LJ, 8701 Morrissette Drive, 

Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 


tkelley on DSK3SPTVN1PROD with NOTICES